Several biodistribution studies have already evaluated 89Zirconium (89Zr)-labelled girentuximab, an anti-CAIX monoclonal antibody (mAb) in renal cell carcinoma [62,63,64]. Here, CA9 is linked to hereditary clear cell renal cell carcinoma.